In vitro absorption and secretory quotients:: Practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates

被引:17
作者
Thiel-Demby, VE
Tippin, TK
Humphreys, JE
Serabjit-Singh, CJ
Polli, JW
机构
[1] GlaxoSmithKline Inc, Preclin Drug Metab & Pharmacokinet, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline Inc, MV CEDD Drug Metab & Pharmacokinet, Res Triangle Pk, NC 27709 USA
关键词
intestinal absorption; drug transporter; P-glycoprotein; permeability; Caco-2; in vitro models;
D O I
10.1002/jps.20166
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The absorptive (AQ) and secretory (SQ) quotients have been proposed as a novel experimental approach to quantify the modulation of intestinal absorption and secretion by P-glycoprotein (Pgp). Because these unidirectional assays inherently assess for the impact of Pgp, conclusions as to whether a compound is a Pgp substrate will be made from the data. Therefore, the objective of this study was to establish the relationship between AQ/SQ and the bidirectional efflux assay and to derive criteria to classify a compound as a Pgp substrate. AQ and SQ parameters were calculated for 331 compounds that had previously been evaluated in the bidirectional assay and the concordance of Pgp substrate classification between these methods assessed by establishing AQ/SQ criteria of increasing magnitude. The AQ and SQ values correctly identified 80 and 85% of the compounds as Pgp substrates/nonsubstrates relative to the bidirectional efflux assay. This study demonstrates that the optimal AQ and SQ value to classify compounds as Pgp substrates was 0.3 and provides a basis to deploy unidirectional efflux assays in the early stages of drug discovery, which would benefit from the twofold increase in throughput over current bidirectional transport assays. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:2567 / 2572
页数:6
相关论文
共 7 条
  • [1] Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
    Doan, KMM
    Humphreys, JE
    Webster, LO
    Wring, SA
    Shampine, LJ
    Serabjit-Singh, CJ
    Adkison, KK
    Polli, JW
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) : 1029 - 1037
  • [2] Role of P-glycoprotein in pharmacokinetics - Clinical implications
    Lin, JH
    Yamazaki, M
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (01) : 59 - 98
  • [3] Polli JW, 2001, J PHARMACOL EXP THER, V299, P620
  • [4] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
    Schinkel, AH
    Jonker, JW
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) : 3 - 29
  • [5] Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers
    Troutman, MD
    Thakker, DR
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (08) : 1200 - 1209
  • [6] Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium
    Troutman, MD
    Thakker, DR
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (08) : 1210 - 1224
  • [7] Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells
    Troutman, MD
    Thakker, DR
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (08) : 1192 - 1199